Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015

Background Uncertainty regarding chemotherapy benefit among breast cancer patients with intermediate Oncotype Dx® recurrence scores (RS; 11–25) led to the TAILORx study. We evaluated chemotherapy use in patients with intermediate RS to determine practice change potential based on the TAILORx results.